Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  lapatinib ditosylate
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PUMA-NER-1301, NCI-2013-01418, 2012-004492-38, UTN U1111-1161-1603, NCT01808573
Lapatinib Ditosylate and Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2008-437, NCI-2013-00670, NCT00881621
Lapatinib Ditosylate and Trastuzumab in Treating Older Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: 10112, NCI-2011-00116, 105241, 115357, NCT01273610
Lapatinib Ditosylate and Everolimus in Treating Patients with HER2 Positive Locally Advanced or Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2010-IIT-Novartis-RAD-001, NCI-2016-00027, HSC 12418, NCT01283789
Targeted Enzyme Inhibitor Therapy in Treating Patients with Advanced Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Thymic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-C-0096, NCI-2013-01478, 110096, P10782, 8639, NCT01306045
Whole-Brain Radiation Therapy with or without Lapatinib Ditosylate in Treating Patients with Brain Metastasis from HER2-Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1119, NCI-2012-01977, CDR0000735353, NCT01622868
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RF-3501, NCI-2014-01403, LAP116153, NCT01711658
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients with HER2-Positive Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1B-12-10, NCI-2013-01086, HS-13-00084, NCT01873833
Buparlisib or Alpelisib and Capecitabine, Trastuzumab, or Lapatinib Ditosylate in Treating Patients with Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 1024, NCI-2013-00951, 11-0060, NCT01300962
Lapatinib Ditosylate and Bortezomib in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2010-533, NCI-2013-00659, NCT01497626
Dabrafenib and Lapatinib Ditosylate in Treating Patients with Refractory Thyroid Cancer That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-061, NCI-2013-01748, 9354, NCT01947023
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
Phase: Phase I
Type: Treatment
Age: 1 to 21
Trial IDs: NMTRC012, NCI-2015-01822, NCT02559778
Trastuzumab, Pertuzumab, and Lapatinib Ditosylate in Measuring Kinome Response in Patients with HER2+ Breast Cancer Undergoing Surgery
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: LCCC 1214, NCI-2014-01407, 13-1826, NCI-2014-00972, NCT01875666
Lapatinib Tosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ABTC-1302, NCI-2014-00634, NCT02101905
Veliparib and Lapatinib Ditosylate in Treating Patients with Triple Negative Metastatic Breast Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: UAB1372, NCI-2015-00265, F131219003, NCI-2014-02253, NCT02158507
Start Over